| Literature DB >> 33641350 |
Justin P Zachariah1, Yunfei Wang1, Jane W Newburger2, Sarah D deFerranti2, Gary F Mitchell3, Ramachandran S Vasan4,5.
Abstract
Background Aortic stiffening begins in youth and antedates future hypertension. In adults, excess weight, systemic inflammation, dyslipidemia, insulin resistance, neurohormonal activation, and altered adipokines are implicated in the pathogenesis of increased aortic stiffness. In adolescents, we assessed the relations of comprehensive measures of aortic stiffness with body mass index (BMI) and related but distinct circulating biomarkers. Methods and Results A convenience sample of 246 adolescents (mean age, 16±2 years; 45% female, 24% Black, and 43% Hispanic) attending primary care or preventive cardiology clinics at 2 tertiary hospitals was grouped as normal weight (N=98) or excess weight (N=148, defined as BMI ≥age- and sex-referenced 85th percentile). After an overnight fast, participants underwent anthropometry, noninvasive arterial tonometry, and assays for serum lipids, CRP (C-reactive protein), glucose, insulin, renin, aldosterone, and leptin. We used multivariable linear regression to relate arterial stiffness markers (including carotid-femoral pulse wave velocity) to BMI z score and a biomarker panel. Carotid-femoral pulse wave velocity was higher in excess weight compared with normal weight group (5.0±0.7 versus 4.6±0.6 m/s; P<0.01). After multivariable adjustment, carotid-femoral pulse wave velocity was associated with BMI z score (0.09 [95% CI, 0.01-0.18]; P=0.04) and with low-density lipoprotein cholesterol (0.26 [95% CI, 0.03-0.50]; P=0.03). Conclusions Higher BMI and low-density lipoprotein cholesterol were associated with greater aortic stiffness in adolescents. Maintaining optimal BMI and lipid levels may mitigate aortic stiffness.Entities:
Keywords: adipokines; arterial stiffness; cholesterol; hypertension; inflammation; obesity; pediatric
Year: 2021 PMID: 33641350 PMCID: PMC8174212 DOI: 10.1161/JAHA.120.018419
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Characteristics
| Characteristics | NW Group | EW Group |
|
|---|---|---|---|
| No. | 98 | 148 | |
| Demographics | |||
| Female sex | 45 (46) | 67 (45) | 1 |
| Age, y | 16±2 | 16±2 | 0.68 |
| White | 28 (28) | 30 (20) | 1 |
| Non‐Hispanic Black | 23 (23) | 30 (20) | 0.88 |
| Non‐Black Hispanic | 26 (27) | 72 (49) | <0.001 |
| Asian | 9 (9) | 2 (1) | 0.005 |
| Native American/Pacific Islander | 3 (3) | 3 (2) | 0.61 |
| Multirace/unknown | 9 (9) | 11 (7) | 0.62 |
| Anthropometric measures | |||
| Height, m | 1.64±0.10 | 1.67±0.09 | 0.01 |
| Weight, kg | 57±11 | 92±21 | <0.001 |
| Waist circumference, cm | 74.3±9.2 | 103.0±13.6 | <0.001 |
| BMI, kg/m2 | 20.9±2.7 | 32.9±6.6 | <0.001 |
| BMI age‐sex percentile, % | 51.2±24.7 | 93.5±10.7 | <0.001 |
| Lifestyle factors | |||
| Secondhand smoking exposure | 5 (5) | 19 (13) | 0.049 |
| Daily soda | 11 (11) | 12 (8) | 0.42 |
| Daily fruit juice | 27 (28) | 20 (14) | 0.006 |
| Daily sports drinks | 11 (11) | 10 (7) | 0.43 |
| Breakfasts per week | 5.0±2.1 | 4.1±2.5 | 0.006 |
| Days with ≥30 min of activity | 4.4±2.1 | 3.8±2.1 | 0.02 |
| Television hours per day | 1.8±1.4 | 2.3±1.4 | 0.006 |
| Biomarkers | |||
| Total cholesterol, mg/dL | 160±39 | 176±40 | 0.001 |
| HDL‐C, mg/dL | 55±14 | 42±12 | <0.001 |
| Triglycerides, mg/dL | 80±47 | 132±75 | <0.001 |
| LDL‐C, mg/dL | 89±33 | 106±36 | <0.001 |
| CRP, mg/L | 0.7±0.8 | 1.3±2.0 | <0.001 |
| Glucose, mg/dL | 84±6 | 83±7 | 0.87 |
| Insulin, µIU/mL | 11.5±16.1 | 20.6±17.2 | <0.001 |
| HOMA‐IR | 2.5±3.7 | 4.3±3.7 | <0.001 |
| Plasma renin activity, ng/mL per h | 1.7±1.2 | 1.7±1.4 | 0.75 |
| Aldosterone, ng/dL | 6.4±4.4 | 7.2±6.5 | 0.53 |
| Aldosterone/renin ratio | 5.3±5.3 | 5.4±4.3 | 0.45 |
| Leptin, ng/mL | 5.0±7.0 | 15.5±11.9 | <0.001 |
Data are given as number (percentage) or mean±SD. BMI indicates body mass index; CRP, C‐reactive protein; EW, excess weight; HDL‐C, high‐density lipoprotein cholesterol; HOMA‐IR, homeostatic model assessment of insulin resistance; LDL‐C, low‐density lipoprotein cholesterol; and NW, normal weight.
Hemodynamic Results Comparing EW With NW Group
| Variable | NW Group | EW Group |
|
|---|---|---|---|
| No. | 98 | 148 | |
| Heart rate, beats per minute | 64±10 | 68±10 | 0.002 |
| Brachial systolic pressure, mm Hg | 114±11 | 124±13 | <0.001 |
| Central systolic pressure, mm Hg | 103±14 | 114±18 | <0.001 |
| Diastolic pressure, mm Hg | 52±8 | 59±10 | <0.001 |
| Carotid‐femoral pulse wave velocity, m/s | 4.6±0.6 | 5.0±0.7 | <0.001 |
| Central pulse pressure, mm Hg | 51±15 | 56±17 | 0.035 |
| Mean arterial pressure, mm Hg | 72±9 | 80±11 | <0.001 |
| Echocardiographic subgroup No. | 82 | 119 | |
| Forward pressure wave amplitude, mm Hg | 50±14 | 54±17 | 0.09 |
| Left ventricular outflow tract diameter, cm | 2.0±0.2 | 2.1±0.2 | 0.002 |
| Characteristic impedance, dynes×s/cm5 | 301±122 | 281±138 | 0.045 |
| Peripheral resistance, dynes×s/cm5 | 2148±860 | 1867±809 | 0.003 |
Data are given as mean±SD. EW indicates excess weight; and NW, normal weight.
Correlations Between Hemodynamic Variables
| Variable | CFPWV | cPP | Zc | FPW | MAP |
|---|---|---|---|---|---|
|
CFPWV
| 1 |
0.15 0.02 |
0.03 0.66 |
0.15 0.04 |
0.30 <0.0001 |
|
cPP | 1 |
0.56 <0.0001 |
0.98 <0.0001 |
0.30 <0.001 | |
|
Zc | 1 |
0.58 <0.0001 |
0.14 0.04 | ||
|
FPW | 1 |
0.28 <0.001 | |||
|
MAP | 1 |
Data are given as Pearson correlation R and the P value. CFPWV indicates carotid‐femoral pulse wave velocity; cPP, central pulse pressure; FPW, forward pulse wave; MAP, mean arterial pressure; and Zc, characteristic impedance.
Linear Regression Results for Hemodynamic Outcome Variables
| Variable | CFPWV | cPP | Zc | FPW | MAP |
|---|---|---|---|---|---|
| BMI | 0.09 (0.01 to 0.18) | 0.06 (0.01 to 0.11) | −0.07 (−0.13 to −0.01) | 0.07 (0.01 to 0.13) | 3.52 (2.16 to 4.88) |
|
| 0.04 | 0.03 | 0.01 | 0.02 | <0.001 |
| LDL‐C | 0.26 (0.03 to 0.50) | −0.21 (−0.36 to −0.06) | |||
|
| 0.03 | 0.007 | |||
| CRP | 0.06 (0.05 to 0.06) | ||||
|
| 0.02 | ||||
| Leptin | −0.09 (−0.14 to −0.04) | −0.09 (−0.15 to −0.04) | |||
|
| <0.001 | 0.002 | |||
| HOMA‐IR | 2.25 (0.35 to 4.15) | ||||
|
| 0.02 | ||||
| Model | 0.18 | 0.24 | 0.13 | 0.19 | 0.34 |
Reported as regression coefficient (95% CI) and the P value. All biomarkers and outcomes (cPP, Zc, and FPW) are natural logarithm transformed for nonnormal distributions. Only biomarkers with P<0.05 for a given outcome are reported. Model R 2 indicates the proportion of variance in the respective hemodynamic outcome accounted for by the significant covariates and biomarkers. Adjustment covariates forced into the model are age, sex, height, heart rate, MAP, and BMI z score. BMI indicates body mass index (age‐ and sex‐referenced z score); CFPWV, carotid‐femoral pulse wave velocity; cPP, central pulse pressure; CRP, C‐reactive protein; FPW, forward pulse wave; HOMA‐IR, homeostatic assessment of insulin resistance; LDL‐C, low‐density lipoprotein cholesterol; MAP, mean arterial pressure; and Zc, characteristic impedance.
Triglycerides and aldosterone/renin ratio were not associated with these vascular stiffness measures.